A review of pharmacogenetic aspects of methotrexate and 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia treatment-Reference-Cited by-同舟云学术

A review of pharmacogenetic aspects of methotrexate and 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia treatment

Published:2021-10-19 Issue:3 Volume:8 Page:79-85
ISSN:2413-5496
Container-title:Russian Journal of Pediatric Hematology and Oncology
language:
Short-container-title:Ross. ž. det. gematol. onkol.

Author:

Gurieva О. D.¹^ORCID,Savelyeva М. I.²^ORCID,Valiev Т. Т.¹^ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia

2. Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia

Abstract

Significant progress in the treatment of acute lymphoblastic leukemia (ALL) in children has resulted from the development of effective chemoand supportive care therapy protocols. The vector of further research is aimed at reducing toxicity and long-term side effects. The study of pharmacogenetic aspects of toxicity of the main drugs used in the treatment of ALL – methotrexate and 6-mercaptopurine – allowed to identify oligonucleotide polymorphisms that correlate with the concentration of the drug in blood, toxic effects and the risk of relapse of ALL. The clinical administration of pharmacogenetic methods remains a challenging task, requiring additional research, which will make it possible to individualize the ALL therapy on the basis of the results of molecular profiling.

Publisher

OOO Grafika

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference39 articles.

1. Demidowicz E., Pogorzała M., Łęcka M., Żołnowska H., Marjańska A., Kubicka M., Kuryło-Rafińska B., Czyżewski K., Dębski R., Kołtan A., Richert-Przygońska M., Styczyński J. Outcome of Pediatric Acute Lymphoblastic Leukemia: Sixty Years of Progress. Anticancer Res 2019;39(9):5203–7. doi: 10.21873/anticanres.13717

2. Maamari D., El-Khoury H., Saifi O., Muwakkit S.A., Zgheib N.K. Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia. Pharmgenomics Pers Med 2020;13:295–317. doi: 10.2147/PGPM.S239602.

3. Shervashidze M.A., Valiev T.T. Sovershenstvovanie programm terapii ostrogo limfoblastnogo leikoza u detei: aktsent na minimal'nuyu ostatochnuyu bolezn'. Onkogematologiya 2020;15(3):12–26. doi: 10.17650/1818-8346-2020-15-3-12-26. [Shervashidze M.A., Valiev T.T. Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease. Onkohematolohyya = Oncohematology 2020;15(3):12–26. (In Russ.)].

4. Pshonkin A.V., Rumyantseva Yu.V., Litvinov D.V., Karelin A.F., Boichenko E.G., Lagoiko S.N., Bydanov O.I., Zharikova L.I., Aleinikova O.V., Tyutikova E.S., Digoeva M.A., Arakaev O.R., Streneva O.V., Shamardina A.V., Sharapova G.R., Myakova N.V., Ponomareva N.I., Khachatryan L.A., Kondratchik K.L., Mansurova E.G., Minkina L.M., Ol'shanskaya Yu.V., Yudina N.B., Gerbek I.E., Shapochnik A.P., Karachunskii A.I. Lechenie ostrogo limfoblastnogo leikoza u podrostkov i molodykh vzroslykh: opyt Moskva– Berlin. Rossiiskii zhurnal detskoi gematologii i onkologii 2016;3(1):35–43. doi: 10.17650/2311-1267-2016-3-1-35-43. [Pshonkin A.V., Rumyantseva Yu.V., Litvinov D.V., Karelin A.F., Boychenko E.G., Lagoyko S.N., Bydanov O.I., Zharikova L.I., Aleynikova O.V., Tyutikova Y.S., Digoeva M.A., Arakaev O.R., Streneva O.V., Shamardina A.V., Sharapova G.R., Myakova N.V., Ponomareva N.I., Khachatryan I.A., Kondratchik K.L., Mansurova Y.G., Minkina L.M., Olshanskaya Yu.V., Yudina N.B., Gerbek I.E., Shapochnik A.P., Karachunskiy A.I. Treatment of acute lymphoblastic leukemia in adolescents and young adults: the experience of the Moscow–Berlin. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2016;3(1):35–43. (In Russ.)].

5. Mei L., Ontiveros E.P., Griffiths E.A., Thompson J.E., Wang E.S., Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev 2015;29(4):243–9. doi: 10.1016/j.blre.2015.01.001.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electroencephlographic predictors of epileptiphorm activity in children with lymphoid tumors under therapy;Medical alphabet;2023-06-29

2. Оценка токсичности терапии метотрексатом на основе фармакогенетического тестирования при остром лимфобластном лейкозе у детей;Pharmacogenetics and Pharmacogenomics;2022-01-26